MJA
MJA InSight
MJA Careers
Narrative review

Systemic lupus erythematosus: an update

Vera Golder and Alberta Hoi
Med J Aust 2017; 206 (5): 215-220.
doi:
10.5694/mja16.01229
Summary

  • Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease predominantly affecting women of childbearing age.
  • New classification criteria for SLE have greater sensitivity and therefore improve the diagnostic certainty for some patients, especially those who may previously have been labelled as having undifferentiated symptoms.
  • Uncontrolled disease activity leads to irreversible end-organ damage, which in turn increases the risk of premature death; early and sustained control of disease activity can usually be achieved by conventional immunosuppressant therapy.
  • The development of biological therapy lags behind that for other rheumatic diseases, with belimumab being the only targeted therapy approved by the Therapeutic Goods Administration.
  • “Treat-to-target” concepts are changing trial design and clinical practice, with evidence-based definition of response criteria in the form of remission and low disease activity now on the horizon.
  • While new therapies are awaited, research should also focus on optimising the use of current therapy and improving the quality of care of patients with SLE.

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease. Predominantly affecting young women, it continues to have an unacceptably high morbidity burden.1 Its clinical heterogeneity often makes diagnosis and management challenging even for experienced physicians.

Vera Golder
Alberta Hoi
Monash University, Melbourne, VIC
Article References: 
Reference Text: 
Urowitz MB, Gladman DD, Ibanez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 2012; 64: 132-137.
Reference Order: 
1
Reference Text: 
Nikpour M, Urowitz MB, Ibanez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1152-1158.
Reference Order: 
2
Reference Text: 
Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012; 64: 4021-4028.
Reference Order: 
3
Reference Text: 
Alarcon GS, McGwin G Jr, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 2001; 45: 191-202.
Reference Order: 
4
Reference Text: 
Mok CC, Ho LY, Cheung MY, et al. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009; 38: 121-127.
Reference Order: 
5
Reference Text: 
Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005; 32: 1706-1708.
Reference Order: 
6
Reference Text: 
Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686.
Reference Order: 
7
Reference Text: 
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
Reference Order: 
8
Reference Text: 
Bortoluzzi A, Furini F, Campanaro F, Govoni M. Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: analysis of a large monocentric cohort with a long-term follow-up. Lupus 2016; doi:10.1177/0961203316671814 [Epub ahead of print].
Reference Order: 
9
Reference Text: 
Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 1997; 40: 1601-1611.
Reference Order: 
10
Reference Text: 
Alba P, Bento L, Cuadrado MJ, et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62: 556-560.
Reference Order: 
11
Reference Text: 
Derksen RH, Bast EJ, Strooisma T, Jacobs JW. A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum. Ann Rheum Dis 2002; 61: 1099-1102.
Reference Order: 
12
Reference Text: 
González-Naranjo LA, Betancur OM, Alarcón GS, et al. Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort. Semin Arthritis Rheum 2016; 45: 675-683.
Reference Order: 
13
Reference Text: 
Golder V, Connelly K, Staples M, et al. Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus 2013; 22: 1425-1430.
Reference Order: 
14
Reference Text: 
Vincent FB, Bourke P, Morand EF, et al. Focus on systemic lupus erythematosus in indigenous Australians: towards a better understanding of autoimmune diseases. Intern Med J 2013; 43: 227-234.
Reference Order: 
15
Reference Text: 
Ugarte-Gil MF, Alarcon GS. Incomplete systemic lupus erythematosus: early diagnosis or overdiagnosis? Arthritis Care Res (Hoboken) 2016; 68: 285-287.
Reference Order: 
16
Reference Text: 
Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72: 1280-1286.
Reference Order: 
17
Reference Text: 
van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777-787.
Reference Order: 
18
Reference Text: 
Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154: 97-101.
Reference Order: 
19
Reference Text: 
Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009; 11: R109.
Reference Order: 
20
Reference Text: 
Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014; 53: 1470-1476.
Reference Order: 
21
Reference Text: 
Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009; 36: 560-564.
Reference Order: 
22
Reference Text: 
Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168-1172.
Reference Order: 
23
Reference Text: 
Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006; 15: 366-370.
Reference Order: 
24
Reference Text: 
Marmor MF, Kellner U, Lai TY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 2016; 123: 1386-1394.
Reference Order: 
25
Reference Text: 
Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity. Rheumatology (Oxford) 2016; 55: 957-967.
Reference Order: 
26
Reference Text: 
Liu LL, Jiang Y, Wang LN, et al. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs 2012; 72: 1521-1533.
Reference Order: 
27
Reference Text: 
Tselios K, Gladman DD, Su J, Urowitz MB. Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. J Rheumatol 2016; 43: 552-558.
Reference Order: 
28
Reference Text: 
Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-64.
Reference Order: 
29
Reference Text: 
Franklyn K, Hoi A, Nikpour M, Morand EF. The need to define treatment goals for systemic lupus erythematosus. Nat Rev Rheumatol 2014; 10: 567-571.
Reference Order: 
30
Reference Text: 
Hoi A, Littlejohn G. Is there still a role for abatacept in the treatment of lupus? Expert Opin Biol Ther 2014; 14: 1345-1350.
Reference Order: 
31
Reference Text: 
Leone A, Sciascia S, Kamal A, Khamashta M. Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol 2015; 11: 109-116.
Reference Order: 
32
Reference Text: 
Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
Reference Order: 
33
Reference Text: 
Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731.
Reference Order: 
34
Reference Text: 
van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71: 1343-1349.
Reference Order: 
35
Reference Text: 
Furie R, Merrill J, Werth VP, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheumatol 2015; 67 Suppl 10. http://acrabstracts.org/abstract/anifrolumab-an-anti-interferon-alpha-receptor-monoclonal-antibody-in-moderate-to-severe-systemic-lupus-erythematosus-sle/ (accessed Jan 2017).
Reference Order: 
36
Reference Text: 
Connelly KL, Kandane-Rathnayake R, Hoi A, et al. Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. Sci Rep 2016; 6: 29909. doi: 10.1038/srep29909.
Reference Order: 
37
Reference Text: 
Kennedy WP, Maciuca R, Wolslegel K, et al. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci Med 2015; 2: e000080.
Reference Order: 
38
Reference Text: 
van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73: 958-967.
Reference Order: 
39
Reference Text: 
Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75: 1615-1621.
Reference Order: 
40
Reference Text: 
Golder V, Kandane-Rathnayake R, Hoi AY, et al. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Res Ther 2016; 18: 260.
Reference Order: 
41
Reference Text: 
Gladman DD, Ibanez D, Ruiz I, Urowitz MB. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol 2013; 40: 630-633.
Reference Order: 
42
Reference Text: 
Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-1274.
Reference Order: 
43
Reference Text: 
Yazdany J, Panopalis P, Gillis JZ, et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009; 61: 370-377.
Reference Order: 
44
Reference Text: 
Yazdany J, Trupin L, Schmajuk G, et al. Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study. BMJ Qual Saf 2014; 23: 659-666.
Reference Order: 
45
Reference Text: 
Ward MM. Hospital experience and mortality in patients with systemic lupus erythematosus: which patients benefit most from treatment at highly experienced hospitals? J Rheumatol 2002; 29: 1198-1206.
Reference Order: 
46
Reference Text: 
Bartels CM, Buhr KA, Goldberg JW, et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol 2014; 41: 680-687.
Reference Order: 
47
Reference Text: 
Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012; 176: 708-719.
Reference Order: 
48
Reference Text: 
Urowitz MB, Ibanez D, Su J, Gladman DD. Modified Framingham Risk Factor Score for systemic lupus erythematosus. J Rheumatol 2016; 43: 875-879.
Reference Order: 
49
Reference Text: 
Wang X, Yan S, Liu C, et al. Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Osteoporos Int 2016; 27: 1413-1423.
Reference Order: 
50

The full contents of this page are only available to subscribers.